Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardio-oncology Pub Date : 2024-08-07 DOI:10.1186/s40959-024-00243-z

Ermanno Nardi, Ciro Santoro, Maria Prastaro, Mario Enrico Canonico, Stefania Paolillo, Giuseppe Gargiulo, Paola Gargiulo, Antonio L M Parlati, Christian Basile, Luca Bardi, Mario Giuliano, Giovanni Esposito

{"title":"Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.","authors":"Ermanno Nardi, Ciro Santoro, Maria Prastaro, Mario Enrico Canonico, Stefania Paolillo, Giuseppe Gargiulo, Paola Gargiulo, Antonio L M Parlati, Christian Basile, Luca Bardi, Mario Giuliano, Giovanni Esposito","doi":"10.1186/s40959-024-00243-z","DOIUrl":null,"url":null,"abstract":"<p><p>Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and surgery interventions. Thus, it is pivotal to decrease morbidity and mortality in this group by providing appropriate care and prevention. In this subset, the risk of thromboembolic and bleeding events is high and the common risk score such as CHA2DS2-VASc and HAS-BLED employed in non-oncologic patients have limited evidence in cancer patients. A paucity of evidence in the setting in individuals having both malignancies and atrial fibrillation entangle the clinician when it comes to therapeutic management. Tailored management is recommended of anticoagulation treatment could be difficult, and there is. In this review, we try to explain the mechanism of AF in cancer patients as well as its management in this setting.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00243-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and surgery interventions. Thus, it is pivotal to decrease morbidity and mortality in this group by providing appropriate care and prevention. In this subset, the risk of thromboembolic and bleeding events is high and the common risk score such as CHA2DS2-VASc and HAS-BLED employed in non-oncologic patients have limited evidence in cancer patients. A paucity of evidence in the setting in individuals having both malignancies and atrial fibrillation entangle the clinician when it comes to therapeutic management. Tailored management is recommended of anticoagulation treatment could be difficult, and there is. In this review, we try to explain the mechanism of AF in cancer patients as well as its management in this setting.

查看原文本刊更多论文

心房颤动与癌症之间的交叉联系：治疗难题。

与普通人群相比，心房颤动在恶性肿瘤患者中更为常见。其病理生理过程包括促炎症状态以及对化疗、放疗和手术干预的夸张炎症反应。因此，通过提供适当的护理和预防措施来降低这一群体的发病率和死亡率至关重要。在这一群体中，发生血栓栓塞和出血事件的风险很高，而在非肿瘤患者中使用的常见风险评分，如 CHA2DS2-VASc 和 HAS-BLED，在癌症患者中证据有限。对于同时患有恶性肿瘤和心房颤动的患者，由于缺乏相关证据，临床医生在进行治疗管理时陷入困境。建议进行量身定制的抗凝治疗可能比较困难，而且也存在这种情况。在这篇综述中，我们试图解释癌症患者心房颤动的机制以及在这种情况下的处理方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊